Dermot McGovern, M.D., Ph.D., FRCP, FACG, AGAF, is a world-renowned clinician, currently Professor of Medicine and Biomedical Science, Director of Translational Medicine at the F. Widjaja Inflammatory Bowel Disease Institute, and Director of the Cedars-Sinai Precision Medicine Initiative.

The McGovern lab utilizes advanced analytics and AI coupled with ‘-omic’ technologies to investigate the underlying causes of and natural history in IBD with the aim to translate findings into the clinic. He was a co-founder of Prometheus Biosciences, leading the efforts to bring anti-TL1A therapy to patients with IBD and other immune mediated and fibrotic diseases. 

Extending diversity of research is a priority for the McGovern lab, who have co-led gene discovery studies in African American, Hispanic, East Asian and Ashkenazi Jewish populations. They have also performed the first large-scale study to determine sex-specific effects in IBD. Dr. McGovern is leading an international effort to develop a new classification for IBD. His group receives funding from the NIH, The Helmsley Charitable Trust, the European Union, The Litwin Foundation, Paul G. Allen Family Foundation, and the Crohn’s and Colitis Foundation.

Dr. McGovern has published over 300 peer-reviewed papers and has been elected to the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP), and in 2024 was awarded the Sherman Prize.